(Q37803236)

23 August 2017

title

Statins in patients with chronic kidney disease: why, who and when? (English)

1 reference

chronic renal insufficiency

23 August 2017

main subject

1 reference

3

Maciej Banach

1 reference

23 August 2017

2

Jacek Rysz

1 reference

23 August 2017

1

Anna Gluba

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

published in

1 reference

23 August 2017

volume

11

1 reference

23 August 2017

issue

16

1 reference

23 August 2017

page(s)

2665-2674

1 reference

The evolving role of statins in the management of atherosclerosis

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Lipoprotein metabolism and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Mechanisms of dyslipidemia of chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

The metabolic syndrome and chronic kidney disease in U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Cardiovascular complications in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Premature cardiovascular disease in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Cardiovascular calcification in patients with chronic renal failure: are we on target with this risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

The role of Toll-like receptors in renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Rosuvastatin in patients undergoing hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effect of pravastatin on cardiovascular events in people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Sudden cardiac death and dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Arterial structure and function in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Study of Heart and Renal Protection (SHARP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Epidemiology and prognostic implications of contrast-induced nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Contrast-induced nephropathy and acute renal failure following emergent cardiac catheterization: incidence, risk factors and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Meta-analysis: the effect of statins on albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Early recognition and prevention of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Statins for improving renal outcomes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Impact of statin treatment on 1-year functional and histologic renal allograft outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Do statins protect the kidney as well as the heart?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

The inflammation hypothesis and its potential relevance to statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Statins and solid organ transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Role and significance of statins in the treatment of hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Effects of atorvastatin on vascular intimal hyperplasia: an experimental rodent model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Clinical experience with ezetimibe/simvastatin in a Mediterranean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of r

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512419

10.1517/14656566.2010.512419

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference